Allergan Pharmaceuticals International Limited

Grunenthal Gmbh

Park Therapeutics, Inc.

Ramesh Boinpally

Joel M Trugman

Michelle Finnegan

Abhijeet Jakate

Annette Christoph

Joachim Ossig

Elke Kleideiter

Rene Fussen

René Fussen

The present disclosure provides methods for the treatment of migraine by the administration of atogepant or a pharmaceutically acceptable salt thereof.

Methods of treating migraine

The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.

Treatment of migraine

The invention relates to Cebranopadol or a physiologically acceptable salt thereof for use in the treatment or the prevention of pain and/or opioid drug dependence in a subject with impaired hepatic and/or renal function.

Cebranopadol for treating pain in subjects with impaired hepatic and/or impaired renal function

Growing community of inventors

Princeton, NJ, United States of America

Ramesh Boinpally